Table 4 of Dejneka, Mol Vis 2008; 14:997-1005.

Table 4. Levels of intact bevasiranib in individual rabbit tissues following intravitreal injection.



Total bevasiranib present in tissue sample (ngs) 24 h following intravitreal injection
Animal ID Treatment Aqueous fluid Vitreous fluid Lens Iris Ciliary Body RPE Choroid Retina
A1/OS D5W <LLOQ <LLOQ <LLOQ <LLOQ NA <LLOQ <LLOQ <LLOQ
A1/OD D5W <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ <LLOQ
B1/OS D5W <LLOQ <LLOQ <LLOQ <LLOQ NA <LLOQ <LLOQ <LLOQ
B1/OD D5W <LLOQ <LLOQ <LLOQ <LLOQ NA <LLOQ <LLOQ <LLOQ
A2/OS Bevasiranib 325.6 (0.02%) >ULOQ <LLOQ 18,358.3 (0.92%) 176.3 (0.01%) 806.8 (0.04%) 214.2 (0.01%) 236.5 (0.01%)
A2/OD Bevasiranib 2,170.5 (0.11%) >ULOQ <LLOQ 1,572.3 (0.08%) 12.7 (0.001%) 422.6 (0.02%) 58.2 (0.003%) 2,335.1 (0.12%)
B2/OS Bevasiranib 3,547.0 (0.18%) >ULOQ <LLOQ 18,943.8 (0.95%) 86.2 (0.004%) 645.3 (0.03%) 382.1 (0.02%) 410.8 (0.02%)
B2/OD Bevasiranib 4,043.0 (0.20%) >ULOQ 16,160.6 (0.81%) 27,534.9 (1.38%) 553.8 (0.03%) >ULOQ 1,298.5 (0.06%) 749.8 (0.04%)
E5/OD Bevasiranib 1,688.9 (0.08%) 114,171.9 (5.71%) <LLOQ 2,371.0 (0.12%) 6,396.6 (0.32%) 2,695.6 (0.13%) 2,139.9 (0.11%) 1,690.2 (0.08%)

Rabbit eyes were treated with 50 μl of D5W or 2 mg bevasiranib, prepared in 50 μl D5W. Levels of bevasiranib were measured in individual rabbit tissues 24 h post-dosing using LNA analysis. The total bevasiranib in tissue is presented in ngs. Percentages in parentheses reflect the percent of total dose recovered from each tissue. Abbreviations: LLOQ means lower limits of quantification; ULOQ means upper limits of quantification; NA means not analyzed.

Dejneka, Mol Vis 2008; 14:997-1005. http://www.molvis.org/molvis/v14/a119

©2008 Molecular Vision http://www.molvis.org/molvis/

ISSN 1090-0535